As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s ...

A recent report from Korea buzzed a Biogen takeover by Samsung. Turns out, Samsung is indeed buying something of Biogen’s, just not the entire company that’s saddled with the Alzheimer’s disease drug ...

Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year ...

Ten years after the formation of biosimilar-focused joint venture Samsung Bioepis, Biogen is finally launching its first U.S. biosimilar. Together with Samsung Bioepis, Biogen is commencing marketing ...

INCHEON, Korea, April 17, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE ®1), a biosimilar to Prolia 2 (denosumab) across ...

Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis can launch Opuviz in the U.S. in January 2027. Opuviz, a biosimilar to Eylea, received FDA ...

This agreement enables Samsung Bioepis to launch Opuviz 2 mg in the United States starting in January 2027. Choi MacDonald continued, "We are well-positioned to successfully launch our aflibercept ...

Samsung Bioepis Co., Ltd. today released its Second Quarter 2026 Biosimilar Market Report, marking the thirteenth edition of the Quarterly Biosimilar Market Report in the United States (US). The ...

INCHEON, KOREA--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept ...